QR Code

Relationship between canagliflozin use and sarcopenia: Real-world data from the United States

Aims: Real-world data were analyzed to evaluate the incidence and risk of sarcopenia for canagliflozin compared with other antihyperglycemic agents (AHAs) including dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), empagliflozin, and dapagliflozin. Mate...

Full description

Saved in:
Main Authors: Zhong Yuan, Jill Hardin, James P. Gilbert, Jordy Mehawej, Saberi Rana Ali, Carolyn Jeffcoat, Sergio Fonseca
Format: Artigo
Language:Inglês
Published: Elsevier 2025-07-01
Series:Diabetes Epidemiology and Management
Subjects:
Real-world data
Type 2 diabetes mellitus
Canagliflozin
Sarcopenia
Propensity scores
Incidence
Online Access:http://www.sciencedirect.com/science/article/pii/S2666970625000289
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items